Richard W. Paul & Associates LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Richard W. Paul & Associates LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,467 shares of the company’s stock after acquiring an additional 128 shares during the quarter. Richard W. Paul & Associates LLC’s holdings in Johnson & Johnson were worth $1,048,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. KMG Fiduciary Partners LLC raised its position in Johnson & Johnson by 54.4% during the 1st quarter. KMG Fiduciary Partners LLC now owns 32,778 shares of the company’s stock valued at $5,185,000 after purchasing an additional 11,548 shares in the last quarter. American National Bank raised its position in Johnson & Johnson by 5.3% during the 1st quarter. American National Bank now owns 73,938 shares of the company’s stock valued at $11,696,000 after purchasing an additional 3,743 shares in the last quarter. M. Kraus & Co raised its position in Johnson & Johnson by 0.5% during the 1st quarter. M. Kraus & Co now owns 53,914 shares of the company’s stock valued at $8,529,000 after purchasing an additional 253 shares in the last quarter. Park Avenue Securities LLC raised its position in shares of Johnson & Johnson by 3.1% in the 1st quarter. Park Avenue Securities LLC now owns 48,942 shares of the company’s stock worth $7,742,000 after acquiring an additional 1,476 shares in the last quarter. Finally, Nexus Investment Management ULC raised its position in shares of Johnson & Johnson by 9.1% in the 1st quarter. Nexus Investment Management ULC now owns 8,376 shares of the company’s stock worth $1,325,000 after acquiring an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Citigroup boosted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen reduced their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.4 %

Johnson & Johnson stock opened at $165.13 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The business’s 50-day simple moving average is $162.98 and its two-hundred day simple moving average is $154.71. The company has a market cap of $397.41 billion, a PE ratio of 10.29, a PEG ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 EPS. Equities analysts anticipate that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.